SCRI Development Innovations
Also known as: Sara Cannon Research Institute | Sarah Cannon | Sarah Cannon Cancer Center | Sarah Cannon Development Innovations | Sarah Cannon Research Insititute | Sarah Cannon Research Instititue (SCRI) | Sarah Cannon Research Institute-Denver | Sarah Cannon Research Institute; Denver, Colorado 80218 USA | Sarah Cannon Research Institute HealthOne, Denver, CO | Sarah Cannon Research Institute, Nashville, Tennessee | Sarah Cannon Research Institute; Nashville, Tennessee 37203, USA | Sarah Cannon Research Institute (SCRI) | Sarah Cannon Research Institute, UK | Sarah Cannon Research Institute United Kingdom | Sarah Cannon Research Institute, United Kingdom | Sarch Cannon Research Institute | SCRI | SCRI Development Innovations, LLC | SCRI Innovations | SCRI-Tennessee Oncology | Tennessee Oncology / Sarah Cannon | The Sarah Cannon Research Institute
Highest phase reached
Phase 3
First clinical trial
Dec 1, 1998Last known activity
Sep 29, 2025
Timeline
1990s
- Jun 1, 1993
SCRI Development Innovations— Founded
Drugs by trial phase (173 distinct, 242 trials)
Phase 3 (22 own, 0 via acquisition)
Phase 2 (113 own, 0 via acquisition)
Phase 1 (38 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma
- Angina, Unstable
- Brain Neoplasms
- Breast Neoplasms
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Transitional Cell
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Corneal Ulcer
- Digestive System Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- GATA2 Deficiency
- Glioblastoma
- Glioma
- Gliosarcoma
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hodgkin Disease
- Hypersensitivity
- Hypoxia
- Infarction
- Infections
- Inflammatory Breast Neoplasms
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Meningioma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Myocardial Infarction
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neoplasms, Unknown Primary
- Neuroendocrine Tumors
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Prostatic Neoplasms
- Rectal Neoplasms
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Syndrome
- Triple Negative Breast Neoplasms
- Ulcer
- Urinary Bladder Neoplasms
Recent trials (50)
- NCT07011576Lead sponsorPhase 2Sep 29, 2025
- NCT06974786Lead sponsorPhase 2Aug 8, 2025
- NCT06773910OfficialPhase 2Mar 31, 2025
- NCT06773910Lead sponsorPhase 2Mar 31, 2025
- NCT05948462Lead sponsorPhase 2Nov 30, 2023
- NCT05948462Study chairPhase 2Nov 30, 2023
- NCT05972135Study chairPhase 2Oct 23, 2023
- NCT05972135OfficialPhase 2Oct 23, 2023
- NCT05972135Lead sponsorPhase 2Oct 23, 2023
- NCT05748834Study chairPhase 2Jul 24, 2023
- NCT05748834Lead sponsorPhase 2Jul 24, 2023
- NCT04906395Overall official - principal investigatorPhase 3Jul 1, 2021
- NCT04990739Study chairPhase 1Jun 30, 2021
- NCT04699630Lead sponsorPhase 2May 3, 2021
- NCT04699630Study chairPhase 2May 3, 2021
Details
- Founded
- Nashville, TN, US Jun 1, 1993
- Last known activity
- Sep 29, 2025
Notes
SCRI Development Innovations (CRO) is a division of the Sarah Cannon Research Institute --- Pre-folding founded info: 2006-01-01 Nashville TN United States https://www.cmocro.com/company/SCRI+Development+Innovations%2C+LLC/index.html ---